DT02 Rec'd PCT/PT0 281

Attorney Docket No. 54061.8101.US01

hereby dertify that this correction dence is being deposited with the U.S. Postar Solice with sufficient postage as first places Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage and I.S. Postar Solice with sufficient postage as first places and I.S. Postar Solice with sufficient postage and I.S. Postar Solice with sufficient places and I.S. Postar Solice with sufficient postage and I.S. Postar Solice with suf

Date: February 23, 2005

By: Rena lov

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: BRONISLAVA GEDULIN, ET AL.

APPLICATION NO.:

10/518,128

FILED:

DECEMBER 14, 2004

FOR: PREVENTION AND/OR TREATMENT OF

INFLAMMATORY BOWEL DISEASE USING

PYY OR AGONISTS THEREOF.

<u>Information Disclosure Statement Within Three Months of</u>
<u>Application Filing or Before First Action – 37 C.F.R. § 1.97(b)</u>

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1. <u>Timing of Submission</u>

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 C.F.R. § 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

\boxtimes	Copies of	of the	following	references	are enc	losed
-------------	-----------	--------	-----------	------------	---------	-------

☐ All cited references

□ References marked by asterisks

The following: The references listed on the enclosed Form PTO-1449 (modified).

Copies of following references can be found in parent U.S. Application No. :					
	All cited references References marked by asterisks The following:				
paten	application was filed after 30 June 2003 and no copies of U.S. ts nor published applications are enclosed (See Notice of Deputy nissioner Kunin on 11 July 2003).				
under comm Autho be an for the the tra accura	ollowing references are not in English. For each such reference, the signed has enclosed (i) a translation of the reference; (ii) a copy of a nunication from a foreign patent office or International Searching rity citing the reference, (iii) a copy of a reference which appears to English-language counterpart, or (iv) an English-language abstract reference prepared by a third party. Applicant has not verified that anslation, English-language counterpart or third-party abstract is an atterpresentation of the teachings of the non-English reference, h, and reserves the right to demonstrate otherwise.				
	All cited references References marked by ampersands The following: Teshima, H., Tari, A., Sumii, K., Yoshihara, M., Ohgoshi, H., Fukuhara, I., Tokumo, K., Haruma, K., Kajiyama, G., Miyachi, Y. and et, a.l. (1987) [Plasma peptide YY-like immunoreactivity in ulcerative colitis, colorectal cancer, and colectomy]. Nippon Shokakibyo Gakkai Zasshi 84, 2681-2687.				

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. <u>Fee Payment</u>



No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

- Applicant further submits that no fee is due in light of the following certification under 37 C.F.R. § 1.97(e) (check only one):
 - In accordance with 37 C.F.R. § 1.97(e)(1), the undersigned hereby states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; or
 - In accordance with 37 C.F.R. § 1.97(e)(2), the undersigned hereby states that no item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c), more than three months prior to the filing of this statement.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2586.

Patent Term Adjustment (37 C.F.R. § 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted, Perkins Coie LLP

Date: 2 23/05

James J. Zhu

Registration No. 52,396

Correspondence Address:

Customer No. 34055
Patent – LA
Perkins Coie LLP
P.O. Box 1208
South Workington 98111 120

Seattle, Washington 98111-1208 Phone: (310) 788.9900

Fax: (310) 788.3399

			IPE	С
		DISCLASURE	26	Application Number
	Confirmation Number			
	Filing Date			
	First Named Inventor			
	Group Art Unit			
	(Use several she		TRANSME	Examiner Name
Sheet	1	of	1	Attorney Docket No.

COMPLETE IF KNOWN					
Application Number	10/518,128				
Confirmation Number					
Filing Date	December 14, 2004				
First Named Inventor	Gedulin, Bronislava				
Group Art Unit					
Examiner Name	Not yet assigned				
Attorney Docket No.	54061.8101.US01				

					U.S.	PATENT DOCUMENTS			
Examiner Initials*	Cite			Code	Name of Patentee or Inventor of Cited Document		Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		For	eign Patent or An			GN PATENT DOCUMENTS	Date of	T	\top
Examiner Cite Kind Code Initials* No. Office NUMBER (if known		Code	Name of Patentee or Applicant of Cited Document	Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т			
		 							4
			OTHER RE	UOD /	LDT A	ION DATENT LITEDATURE D	COUNTY		ᆚᆛ
Examiner	Cite		Include name of t	he auth	or (in C	CAPITAL LETTERS), title of the article	(when appropriate)		Π
Initials*	No.	(, , ,),					T		
	AA	El-Salhy, M., Danielsson, A., Stenling, R. and Grimelius, L. (1997) Colonic endocrine cells in inflammatory bowel disease. <i>J Intern Med</i> 242 , 413-419.							
	АВ	Koch, T.R., Roddy, D.R., Carney, J.A. and Go, V.L. (1988) Peptide YY concentrations in normal ileum and colon and in idiopathic inflammatory bowel disease. <i>Dig Dis Sci</i> 33, 1322-1328.							
	AC	Tari, A., Teshima, H., Sumii, K., Haruma, K., Ohgoshi, H., Yoshihara, M., Kajiyama, G. and Miyachi, Y. (1988) Peptide YY abnormalities in patients with ulcerative colitis. <i>Jpn J Med</i> 27 , 49-55.							
	AD	Ternent, C.A., Staab, P., Thorson, A.G., Blatchford, G.J., Christensen, M.A., Thompson, J.S., Lanspa, S.J., Meade, P.G., Cali, R.A., Falk, P.M., Sentovich, S.M. and Adrian, T.E. (1998) Ileoanal pouch function and release of peptide YY. <i>Dis Colon Rectum</i> 41 , 868-874.							
	AE	Teshima, H., Tari, A., Sumii, K., Yoshihara, M., Ohgoshi, H., Fukuhara, I., Tokumo, K., Haruma, K., Kajiyama, G., Miyachi, Y. and et, a.l. (1987) [Plasma peptide YY-like immunoreactivity in ulcerative colitis, colorectal cancer, and colectomy]. <i>Nippon Shokakibyo Gakkai Zasshi</i> 84, 2681-2687.							
		M							
			_				19/31		

EXAMINER		DATE CONSIDERED			
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).				